As we enter 2026, the global biopharmaceutical industry stands at an unprecedented crossroads of innovation and transformation. Emerging technologies—represented by Cell and Gene Therapy (CGT), bioconjugates, multispecific antibodies, RNA therapeutics, and AI-driven drug discovery—are fundamentally reshaping the paradigms of disease treatment,especially in Asia region. 

AsiaBIO Innovation Summit 2026 Singapore will delve into the deepening and expansion of Cell and Gene Therapy, exploring the  revolutionary shift from ex-vivo programming to in-vivo in-situ treatments, alongside strategic breakthroughs in tackling solid tumors. We will also focus on the precision and increasing complexity of bioconjugates and multispecific molecules, specifically highlighting the design and development of XDC therapeutics and T-cell Engagers (TCE). Furthermore, the event will bridge the gap between emerging modalities and  large-scale manufacturing, analyzing innovations in siRNA and AI-powered peptides, as well as the industrialization of cutting-edge delivery technologies.